Efficiency and toxmcity of the fludarabine and cyclophosphamide combined therapy in relapsed resistant patients with B-cell chronic lymphocytic leukaemia (CLL) - Polish multicenter study

被引：0
|
作者：
Kowal, M [1 ]
Dmoszynska, A [1 ]
Jawniak, D [1 ]
Lewandowski, K [1 ]
Wegrzyn, J [1 ]
Wolowiec, D [1 ]
Piszcz, J [1 ]
Roznowski, K [1 ]
机构：
[1] Med Acad, Dept Hematooncol, Lublin, Poland
来源：
7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION | 2002年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We present results of the fludarabine and cyclophosphamide regimen in relapsed/resistant 63 patients with CLL-the first Polish multi- centre trial. Purine analogues (PA) such as fludarabine (F) induce higher remission rates(RR) than conventional chemotherapy in advanced CLL, particulary in patients resistant to alkylating agents (AA)(3, 4). Further studies showed a synergistic activity with other drugs in particular cyclophosphamide (C)(8). The combination of F and C seem to produce a high RR in patients refractory to AA or single-agent of PA. We report here the results of first Polish multicenter study of FC regimen in patients with advanced B-CLL.
引用
收藏
页码：211 / 214
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL) - Polish multicentre study
    Kowal, M
    Dmoszynska, A
    Lewandowski, K
    Hellmann, A
    Wegrzyn, J
    Skotnicki, AB
    Wolowiec, D
    Kuliczkowski, K
    Piszcz, J
    Kloczko, J
    Roznowski, K
    Komarnickif, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (06) : 1159 - 1165
  • [2] Combined therapy with Fludarabine and Cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas
    Zaja, F
    Rogato, A
    Russo, D
    Marin, L
    Silvestri, F
    Baccarani, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 59 (05) : 327 - 328
  • [3] Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
    Bosch, F
    Ferrer, A
    López-Guillermo, A
    Giné, E
    Bellosillo, B
    Villamor, N
    Colomer, D
    Cobo, F
    Perales, M
    Esteve, J
    Altés, A
    Besalduch, J
    Ribera, JM
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (04) : 976 - 984
  • [4] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [5] Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL).
    Bosch, F
    Perales, M
    Cobo, F
    Esteve, J
    Rafel, M
    LopezGuillermo, A
    Ribera, JM
    Campo, E
    Montserrat, E
    BLOOD, 1997, 90 (10) : 2360 - 2360
  • [6] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [7] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [8] Outcome in 203 patients (PTS) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX): Retreatment with fludarabine (FLU).
    Thomas, D
    O'Brien, S
    Kantarjian, H
    Giles, FJ
    Lerner, S
    Keating, MJ
    BLOOD, 1998, 92 (10) : 102A - 103A
  • [9] Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).
    Tedeschi, A
    Montillo, M
    Miqueleiz, S
    Draisci, M
    Ricci, F
    Scarpati, B
    Mura, ME
    Crugnola, M
    Morra, E
    BLOOD, 2005, 106 (11) : 341B - 341B
  • [10] Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukemia (CLL):: Final results of a phase II study.
    Bosch, F
    Ferrer, A
    López-Guillermo, A
    Giné, E
    Cobo, F
    Perales, M
    Esteve, J
    Villamor, N
    Colomer, D
    Bellosillo, B
    Ribera, JM
    Altes, A
    Besalduch, J
    Montserrat, E
    BLOOD, 2001, 98 (11) : 634A - 634A
12345